Status:
NOT_YET_RECRUITING
Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures
Lead Sponsor:
Zhejiang University
Collaborating Sponsors:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Nanjing Medical University
Conditions:
Pancreatic Cancer Resectable
Eligibility:
All Genders
Brief Summary
Prospective inclusion of 1000 patients with pancreatic cancer (early-stage pancreatic cancer accounts for approximately 75% of cases), 1000 patients with benign pancreatic diseases, and 1000 healthy i...
Detailed Description
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers and currently ranks as the seventh leading cause of cancer-related deaths in China. The nonspecific symptoms of early PDAC...
Eligibility Criteria
Inclusion
- Sign the informed consent form;
- Initial diagnosis as patients with pancreatic cancer, patients with benign pancreatic lesions, or healthy controls.
Exclusion
- History of other malignancies;
- Presence of organ dysfunction;
- Concurrent immunodeficiency syndrome, active tuberculosis, HIV infection, etc.;
- Allogeneic transplantation requiring immunosuppressive therapy;
- Poor follow-up compliance.
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT06495749
Start Date
August 1 2024
End Date
December 31 2027
Last Update
July 16 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital, Medical College of Zhejiang University
Hangzhou, Zhejiang, China, 310003
2
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310009